MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2025 International Congress

    The Effect of Melatonin on Sleep Quality and Daytime Sleepiness in Parkinson’s Disease: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials

    A. Zrineh, R. Akwan, MM. Elsharkawy, B. Douden, W. Sleibi, M. Eldesouki (Al-Quds, State of Palestine)

    Objective: This study aims to systematically quantify the impact of melatonin on sleep quality and daytime sleepiness in individuals diagnosed with Parkinson’s disease (PD). Background:…
  • 2025 International Congress

    Subdomain-specific cognitive decline and its effect on caregiver burden in Mexican population living with Parkinson’s Disease.

    G. Martin-Mafud, A. Hernández-Medrano, E. Ramírez-Benitez, A. Cervantes-Arriaga, M. Rodríguez-Violante, D. Ulloa-Hernández, M. Velasco-Delgado (Mexico City, Mexico)

    Objective: To determine whether different subdomains of the MoCA associate with caregiver burden. Background: Caregivers improve the quality of life for Parkinson's patients (PwP), despite…
  • 2025 International Congress

    Qualitative research in advanced Parkinson’s disease: Exploring salient symptoms and suitability of the MDS-NMS from the patient, caregiver, and clinician perspective

    N. Williamson, A. Lydon, S. Wallace, E. Taylor, M. Chaudry, H. Bradley, R. Williams-Hall, P. Boccon-Gibod, K. Raphael, E. Stevens, P. Odin, A. Antonini, M. Biagioni (Bollington, United Kingdom)

    Objective: To identify which non-motor symptoms (NMS) are most relevant in an advanced Parkinson’s Disease (PD) population and determine the suitability of the International Parkinson…
  • 2025 International Congress

    Assessing Physiotherapy’s Role in Parkinson’s Disease Functionality in India: A Case Report

    K. Thangavelu (Gurugram, India)

    Objective: To find out the Assessing Physiotherapy's Role in Parkinson’s Disease Functionality in India: A Case Report Background: This case report explores the impact of…
  • 2025 International Congress

    Wearable-based digital measures from the Verily Study Watch can detect concurrent symptomatic treatment effects in a subset of early-stage Parkinson’s disease ORCHESTRA trial participants

    B. Bloem, V. Hinson, L. Gaetano, E. Goikoetxea, K. Ray, F. Ambrosetti, V. Ticcinelli, M. Key Prato, A. Pethe, C. Serrano Amenos, J. Trzebinski, S. Warma, A. Khanna, Z. Ali (Nijmegen, Netherlands)

    Objective: To investigate the effect of concurrent symptomatic treatment (ST) on digital measures collected in ORCHESTRA (NCT04658186). Background: Minzasolmin is an oral small molecule that…
  • 2025 International Congress

    Proof-of-Concept Study Design Leveraging Digital Biomarkers to Enhance Statistical Power and Reduce Sample Size in PD Trials

    S. Hendrix, J. Christensen, S. Jackson, P. O'Keefe, K. Hendrix, S. Dheerendra, F. Nahab, S. Dickson (Millcreek, USA)

    Objective: Parkinson's disease clinical studies for disease modifying therapies face challenges of large sample size and long study duration due to subtle changes at early…
  • 2025 International Congress

    A randomised controlled feasibility study of a technology-assisted home-based aerobic exercise program for individuals with Parkinson’s disease

    S. Neo, Z. Yee, W. Li, HL. Ng, R. Hoe, C. Chung (Singapore, Singapore)

    Objective: The study evaluates the effectiveness of Combat PD, a mobile app designed to remotely deliver and monitor gamified aerobic exercise in promoting adherence and…
  • 2025 International Congress

    A Phase II Randomized, Parallel, Double-blind, Placebo-controlled Study of the Efficacy and Safety of WD-1603 in Subjects with Parkinson’s Disease

    X. Wei, L. Chen, X. Hu, J. Guo, C. Liu, J. Wang (Shanghai, China)

    Objective: To investigate the effectiveness, safety and pharmacokinetics of WD-1603 carbidopa-levodopa controlled-release tablets in subjects with Parkinson's disease. Background: The development of drug products that…
  • 2025 International Congress

    A Systematic Site Selection Approach to Ensure Efficient and Diverse Participant Recruitment to a Large-Scale Multi-Arm, Multi-Stage Platform Trial for Parkinson’s

    G. Mills, M-L. Zeissler, O. Bandmann, R. Barker, J. Carpenter, S. Collins, J. Duffen, S. Gandhi, L. Houlden, C. Gonzalez-Robles, C. Mcalpine, K. Mcfarthing, C. Pugh, A. Schapira, A. Schrag, C. Shakeshaft, T. Foltynie, C. Carroll (London, United Kingdom)

    Objective: To select up to 40 delivery sites to successfully recruit and retain a participant population representative of people with Parkinson’s disease (PwP) in the…
  • 2025 International Congress

    Peripheral insulin resistance may predict exenatide treatment response in Parkinson’s disease

    N. Vijiaratnam, C. Girges, J. Dickson, C. Caroll, M. Silverdale, M. Hu, G. Duncan, K. Chaudhuri, S. Gandhi, D. Athauda, Y. Li, N. Greig, K. Chowdhury, T. Foltynie (London, United Kingdom)

    Objective: To explore if the glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide could modify the course of Parkinson’s disease (PD) and if peripheral insulin resistance (IR) mightdifferentially impact on this. Background: Exenatide…
  • « Previous Page
  • 1
  • …
  • 209
  • 210
  • 211
  • 212
  • 213
  • …
  • 553
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley